Three Treatment Council’s major analyses for 2022 initiated in Denmark

14

Jan 2022

On December 9, 2021, the Treatment Council (Behandlingsråd), during its meeting, approved three topics selected for developing the so-called major analyses (større analyser) in 2022. The approved topics include handheld focused ultrasound in emergency medicine, artificial intelligence (AI) as decision support for colonoscopy, and intelligent/high-tech beds for use in intensive care units.

The analysis on the topic of handheld focused ultrasound in emergency medicine is intended to examine how handheld, pocket-sized ultrasound equipment should be introduced for focused point-of-care ultrasound examinations in emergency rooms.

The analysis concerning AI as decision support for colonoscopy is aimed to answer two research questions:

  • Should additional, AI-based, real-time decision support be used in colonoscopic examinations for colorectal cancer - and if so
  • Are there any significant differences between AI-based, real-time, decision support tools for use in colorectal cancer colonoscopic examinations.

The fourth proposed topic was dedicated to patient-centered diabetes technology. During the meeting, it was decided to limit the analysis to the use of glucose meters in adults with type 1 diabetes and commissioned the Chairman of the Council together with the future chair of the relevant professional committee to further qualify and define the final proposal for the analysis.

The Treatment Council is a new body for assessing treatments and health technologies that became fully operational in late May 2021. The Treatment Council is expected to prepare 2-3 major analyses annually. The analyses are based on more fundamental topics concerning treatment regimens or approaches or organization of treatment. Based on the received proposals, the Board of the Danish Regions selects 2-3 analysis topics once a year, which constitute the Council's annual program for major analyses.

The full details in Danish can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.

The latest related news

28

Jan 2022

On December 26, 2021, the new health app was introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by health insurers. In total, 28 health apps are now available at the DiGA Directory.

Read more

27

Jan 2022

On December 17, 2021, the Belgian Health Care Knowledge Center (KCE) published a health services research report “Evidence gaps for drugs and medical devices at market entry in Europe and potential solutions”. In this report, KCE examined the lack of comparative evidence health technology assessment (HTA) agencies and payers face in evaluating new medicinal products and high-risk medical devices at market entry.

Read more

24

Jan 2022

In spring 2022, a new reimbursement system for remote consultations will be launched with new reimbursement codes and conditions.

Read more

21

Jan 2022

In December 2021, the National Institute for Health Research (NIHR) in England released two MedTech-related reports in its Health Technology Assessment (HTA) Journal, which concerned improving continence in children and young people with neurodisability, and augmented trabeculectomy in glaucoma. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.

Read more

19

Jan 2022

The French National Authority for Health (HAS) released new recommendations about add-on reimbursement of medical devices and medical aids from the meetings of the National Commission for Evaluation of Medical Devices and Health Technologies (CNEDiMTS) in December 2021. More than 15 recommendations were published in relation to the registration, modification of registration conditions, renewal of registration of devices in the List of reimbursable products and services (LPPR). Opinions concern cardiovascular, orthopedic, ENT devices, as well as medical aids. Except for this, CNEDiMTS published an opinion about transitional coverage (a newly established pathway for reimbursement) for a cardiovascular device.

Read more